21
Jun
2018
Impact in More Ways Than One: Tony Coles on The Long Run Podcast
I’m happy to introduce the latest guest on The Long Run podcast — Tony Coles. He is the co-founder and CEO of Yumanity Therapeutics, a Cambridge, Mass.-based company doing drug discovery work against neurodegenerative diseases. That means Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (Lou Gehrig’s disease). This is a fascinating time to be focused on neurodegenerative diseases. The...Read More 
Share:
19
Jun
2018
So You Want To Get Into Biotech…Part 2: Banana Peel? What Banana Peel?
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
18
Jun
2018
So You Want To Get Into Biotech…Part 1: Many Stories, Many Paths
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
15
Jun
2018
Bluebird Gene Therapy Holding Up, CRISPR Gyrations, and a Clever Antibiotic Business Idea
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
13
Jun
2018
EHA18 Preview: Blood Drugs to Watch in Stockholm
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
8
Jun
2018
BIO18 Reflections, Axovant and Ophthotech Reboot with Gene Therapy & More
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
6
Jun
2018
From Hoop Dreams to the Biopharma Big Time: Rob Perez on The Long Run
Today’s guest on the show is Rob Perez. He grew up in a lower-middle class household in Los Angeles. Had some hoop dreams that never quite materialized. No big deal. Perez found he had a knack for sales, and paid his way through college by working at fitness centers. Chance brought him into the pharmaceutical sales business. He liked meeting...Read More
Share:
5
Jun
2018
Blazing a Trail With High-Tech Treatments of the Future
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
1
Jun
2018
Start of a Drug: Square Pegs, Round Indications (part 3 of 3)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
29
May
2018
Start of a Drug: Blueprint for Building a Bridge Across Valley of Death (part 2 of 3)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
23
May
2018
Re-Starting a Company, Keeping Hope Alive: Chip Clark on The Long Run
Today’s guest on The Long Run is Chip Clark. He’s the CEO of Cambridge, Mass.-based Genocea Biosciences. This vaccine platform company got into a jam last summer. It completed a Phase II trial with its lead therapeutic vaccine for genital herpes. Clark tried to insist the trial was a success and the product had a future. The market disagreed. The...Read More
Share:
21
May
2018
Start of a Drug: A ‘Fortuitous’ Collaboration (part 1 of 3)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
9
May
2018
Charting His Own Entrepreneurial Course: Ethan Perlstein on The Long Run
Today’s guest on The Long Run podcast is Ethan Perlstein. He’s outspoken on social media, unafraid to occasionally rattle cages with the industry powers that be. He’s followed an unusual entrepreneurial path, starting a Public Benefit company, raising money from non-traditional sources, embracing ‘radical transparency,’ building an unusual model-organism based platform for drug discovery, and using his Internet savvy to...Read More
Share:
4
May
2018
Luna DNA Brings Blockchain and Genomics Together
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
25
Apr
2018
What Can You Do With Genomics and AI? Alice Zhang on The Long Run
Today’s guest on The Long Run podcast is Alice Zhang. Let’s start with some basic background. Zhang studied systems biology at Princeton, graduated with honors, enrolled in an MD/PHD program at UCLA/Caltech, stayed there five years, quit, moved to Silicon Valley, and co-founded a company dedicated to using her knowledge for neurodegenerative drug discovery. She has been named among the...Read More
Share:
20
Apr
2018
Harnessing What Was There All Along. Book Review of ‘A Cure Within’
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
16
Apr
2018
Kineta and Genentech Team Up to Combat Chronic Pain
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
11
Apr
2018
The Immune Sequencing Frontier: Harlan and Chad Robins on The Long Run
Today on The Long Run are a pair of guests — Harlan and Chad Robins. They are the brothers who co-founded Seattle-based Adaptive Biotechnologies almost a decade ago. Chad is the CEO, and Harlan is the head of innovation. Adaptive, for those unfamiliar, has a specialized focus on sequencing regions of B-cells and T-cells of the adaptive immune system where...Read More
Share:
6
Apr
2018
Challenges in Creating and Distributing Mobile Health Tools: Q&A with Dr. Heather Evans of mPOWEr
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
28
Mar
2018
Teaching and Mentoring the Next Generation: Vicki Sato on The Long Run Podcast
Today’s guest on The Long Run podcast is Vicki Sato. She’s one of the biotech industry’s pioneers. Sato started out as a classic academic scientist on the Harvard faculty. Beginning in the mid-1980s, and for about 20 years, the next phase of her career was as an executive at Biogen and Vertex Pharmaceuticals. Her fingerprints are all over a number...Read More
Share:
